HUMATE-P provides bleed control across all VWD types,
including type 3—the most severe
HUMATE-P provides bleed control across all VWD types, including type 3—the most severe
Connect with us
Meet with your CSL Behring Associate Director of Corporate Accounts.
Schedule a meeting
About von Willebrand disease (VWD)
VWD is the most common bleeding disorder, affecting up to 1% of the US population, or about 3.2 million Americans. VWD occurs with equal frequency among men and women, although women tend to be diagnosed more often due to heavy or abnormal menstrual and/or postpartum bleeding.1
Explore more clinical information here.
What is HUMATE-P?
HUMATE-P is a human plasma–derived von Willebrand factor/factor VIII (VWF/FVIII) concentrate that is indicated for use in adults and pediatric patients with VWD for the treatment of spontaneous and trauma-induced bleeding episodes and the prevention of excessive bleeding during and after surgery. HUMATE-P is not indicated for the prophylaxis of spontaneous bleeding episodes in VWD. HUMATE-P is also indicated for the treatment and prevention of bleeding in adults with hemophilia A.
Please see full prescribing information.
What are the key benefits?
HUMATE-P has been studied for more than 30 years.2
#1 PRESCRIBED
HUMATE-P is the #1 prescribed VWF/FVIII concentrate treatment.3*
RELIABLE CONTROL
HUMATE-P provides reliable hemostatic control for all VWD types.
PROVEN FOR ALL PATIENT
AGES
HUMATE-P can be taken by infants, children, adolescents, and adults with VWD.
*VWF market assessment. Third-party market reserarch.
HUMATE-P has a proven safety profile built on a large body of evidence in VWD2
Want to learn more?
Meet with your CSL Behring Associate Director of Corporate Accounts.
